Key result
A high monocyte to high-density lipoprotein ratio was associated with a 72% increased risk of long-term major adverse cardiac events (HR 1.72) compared to a low ratio in patients with coronary heart disease.
Why the study?
The monocyte to high-density lipoprotein cholesterol ratio is linked to coronary atherosclerotic heart disease, but its utility for predicting mortality and major adverse cardiac events in CHD required meta-analytic evaluation.
Does a high monocyte to high-density lipoprotein cholesterol ratio predict mortality and MACEs in patients with coronary heart disease?
Meta-Analysis (n=11,345)
Does a high monocyte to high-density lipoprotein cholesterol ratio predict mortality and MACEs in patients with coronary heart disease?
Hazard Ratio: 1.72 (95% CI 1.36–2.18)
p-value: p=<0.001
A high monocyte to high-density lipoprotein cholesterol ratio is a significant prognostic indicator for increased long-term mortality and MACEs in patients with coronary heart disease.
MHR may refine CHD prognosis; leaves open its incremental value for risk stratification pending prospective validation.
BACKGROUND: A novel inflammation-related biomarker, the monocyte to high-density lipoprotein cholesterol ratio (MHR), had a great relation to the development and prognosis of coronary atherosclerotic heart disease. Current study was to investigate whether the MHR was a potential tool in predicting the mortality and major adverse cardiac events (MACEs) in patients suffering coronary heart disease (CHD) by meta-analysis. METHODS: The Cochrane Library, PubMed, MEDLINE, Scopus, EMBASE, and Web of science were searched for relevant cohort studies published prior to February 10, 2022. The association between MHR and mortality/MACEs was analyzed in patients with CHD. Hazard ratios (HR) with 95% confidence interval (CI) were calculated to estimate the strength of association. RESULTS: In the meta-analysis, a total of 9 studies of 11,345 patients with CHD were included. Compared with the low level of MHR group, the high MHR value was associated with higher long-term MACEs (HR = 1.72 95% CI 1.36-2.18, P < .001), long-term mortality (HR = 1.71, 95% CI 1.10-2.66, P = .017), and in-hospital mortality/MACEs (HR = 2.82, 95% CI = 1.07-7.41, P = .036). CONCLUSIONS: This study suggested that increased MHR value might be associated with higher long-term mortality and long-term MACEs in CHD patients. MHR might serve as a potential prognostic indicator for risk stratification in patients with CHD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) conducted a meta-analysis in Coronary heart disease (n=11,345). High monocyte to high-density lipoprotein ratio (MHR) vs. Low monocyte to high-density lipoprotein ratio was evaluated on Long-term major adverse cardiac events (MACEs) (HR 1.72, 95% CI 1.36-2.18, p=<0.001). A high monocyte to high-density lipoprotein ratio was associated with a 72% increased risk of long-term major adverse cardiac events (HR 1.72) compared to a low ratio in patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: